Literature DB >> 13437294

Tumor progression.

L FOULDS.   

Abstract

Keywords:  NEOPLASMS/pathology

Mesh：

Year:  1957        PMID： 13437294

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  11 in total

Review 1.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

2.  What history tells us XXVIII. What is really new in the current evolutionary theory of cancer?

Authors:  Michel Morange
Journal:  J Biosci       Date:  2012-09       Impact factor: 1.826

3.  Characterization of the progressive sublines derived from a weakly malignant cloned cell line, ER-1, co-inoculated subcutaneously with a foreign body.

Authors:  J Hamada; H Nagayasu; T Kawano; T Mizutani; D Nakata; M Hosokawa; N Takeichi
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

Review 4.  Defining the Hallmarks of Metastasis.

Authors:  Danny R Welch; Douglas R Hurst
Journal:  Cancer Res       Date:  2019-05-03       Impact factor: 12.701

5.  Acquisition of in vitro growth autonomy during B16 melanoma malignant progression is associated with autocrine stimulation by transferrin and fibronectin.

Authors:  C W Stackpole; S S Kalbag; L Groszek
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-03       Impact factor: 2.416

6.  MFSD2A is a novel lung tumor suppressor gene modulating cell cycle and matrix attachment.

Authors:  Monica Spinola; Felicia S Falvella; Francesca Colombo; James P Sullivan; David S Shames; Luc Girard; Paola Spessotto; John D Minna; Tommaso A Dragani
Journal:  Mol Cancer       Date:  2010-03-17       Impact factor: 27.401

7.  Scar cancers: pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4) - IX.

Authors:  E R Fisher; A S Palekar; R Sass; B Fisher
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

Review 8.  It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy.

Authors:  Jason R Westin; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2012-11-30       Impact factor: 6.261

9.  Progression of weakly malignant clone cells derived from rat mammary carcinoma by host cells reactive to plastic plates.

Authors:  J Hamada; N Takeichi; F Okada; J Ren; X Li; M Hosokawa; H Kobayashi
Journal:  Jpn J Cancer Res       Date:  1992-05

Review 10.  Targeting the mu-Opioid Receptor for Cancer Treatment.

Authors:  Hao Zhang; Di Zhou; Jiahui Gu; Mengdi Qu; Kefang Guo; Wankun Chen; Changhong Miao
Journal:  Curr Oncol Rep       Date:  2021-08-03       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.